Rotem Amir
Internal Medicine · Hallandale Beach, FLNPI 1871603290
Payments from drug & device makers
Across 205 payments — averaging $61.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intra-sana Laboratories$9K
- Novo Nordisk$1K
- Lilly USA, LLC$273
- AstraZeneca$252
- Sanofi-aventis U.S. LLC$205
- Boehringer Ingelheim$192
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$8,00063%
- Food & beverage$4,59736%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intra-sana Laboratories | 12 | $8,534 |
| Novo Nordisk | 53 | $1,282 |
| Lilly USA, LLC | 17 | $273 |
| AstraZeneca | 14 | $252 |
| Sanofi-aventis U.S. LLC | 12 | $205 |
| Boehringer Ingelheim | 10 | $192 |
| GSK | 10 | $185 |
| Valeritas, Inc. | 6 | $180 |
| Rhythm Pharmaceuticals, Inc. | 3 | $162 |
| Zealand Pharma US, Inc. | 4 | $127 |
| Novartis | 6 | $125 |
| Astellas Pharma US Inc | 5 | $101 |
| Merck | 5 | $97 |
| Currax Pharmaceuticals LLC | 6 | $96 |
| Intuitive Surgical | 1 | $86 |
| Amarin Pharma, Inc. | 5 | $85 |
| Vivus LLC | 2 | $82 |
| Melinta Therapeutics, LLC | 4 | $81 |
| Zyla Life Sciences, Inc. | 4 | $69 |
| Nalpropion Pharmaceuticals LLC | 4 | $57 |
| Pfizer | 3 | $55 |
| Grifols USA, LLC | 4 | $50 |
| AbbVie | 3 | $41 |
| Radius Health, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $29 |
| Amgen | 2 | $27 |
| Abbott | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Medtronic | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$8,374
- GLYCATE$8,374
- Reltone 400 Mg$8,374
- Tresiba$126
- Saxenda$125
- Wegovy$125
How this compares
$12,611 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 23 | $24,415 |
| OzempicSemaglutide | 11 | $10,612 |
| Metformin Hcl | 14 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $273 | $24,41523 claims |
| Novo NordiskOzempic | $1,282 | $10,61211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Hallandale Beach
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.